Novartis’ (NVS) Neutral Rating Reiterated at JPMorgan Chase & Co.

Novartis (NYSE:NVS)‘s stock had its “neutral” rating reissued by investment analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. Leerink Swann increased their price target on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Finally, Barclays lowered shares of Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $85.32.

Shares of Novartis (NYSE NVS) opened at $86.88 on Thursday. Novartis has a one year low of $69.53 and a one year high of $87.29. The firm has a market cap of $227,480.00, a PE ratio of 30.92, a P/E/G ratio of 2.32 and a beta of 0.74. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The company had revenue of $12.41 billion during the quarter, compared to analyst estimates of $12.21 billion. During the same period in the prior year, the firm earned $1.23 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. analysts anticipate that Novartis will post 4.79 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in NVS. Alliancebernstein L.P. lifted its position in shares of Novartis by 2.7% during the second quarter. Alliancebernstein L.P. now owns 56,504 shares of the company’s stock valued at $4,716,000 after buying an additional 1,483 shares during the last quarter. Nationwide Fund Advisors lifted its position in shares of Novartis by 266.8% during the second quarter. Nationwide Fund Advisors now owns 196,685 shares of the company’s stock valued at $16,417,000 after buying an additional 143,069 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Novartis by 25.3% during the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock valued at $296,299,000 after acquiring an additional 717,186 shares in the last quarter. UBS Asset Management Americas Inc. increased its holdings in shares of Novartis by 3.5% during the second quarter. UBS Asset Management Americas Inc. now owns 28,160 shares of the company’s stock valued at $2,351,000 after acquiring an additional 952 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Novartis during the second quarter valued at about $424,000. 10.85% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Novartis’ (NVS) Neutral Rating Reiterated at JPMorgan Chase & Co.” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2018/01/18/novartis-nvs-neutral-rating-reiterated-at-jpmorgan-chase-co.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit